Whether Almonertinib can cure lung cancer and evaluation of treatment expectations

Almonertinib (Almonertinib, trade name: osimertinib-like drug) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor agent (TKI), mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR mutations. The drug can specifically inhibit EGFR sensitive mutations and T790M drug-resistant mutations, thereby blocking tumor cell proliferation and survival signals and delaying disease progression. Although ametinib has shown significant efficacy in targeted therapy, it is currently unable to cure lung cancer. The main goal of treatment is to prolong the progression-free survival (PFS) and overall survival (OS) of patients, while improving the quality of life.

In clinical trials and real-world studies, ametinib has shown high objective response rates (ORR) and disease control rates (DCR). For patients with advanced or metastatic EGFR mutated NSCLC, ametinib can effectively reduce tumor volume, delay disease recurrence, and control the progression of brain metastases to a certain extent. Although most patients can achieve significant short-term effects, since lung cancer is a complex malignant tumor and there are still drug-resistant mechanisms, the possibility of complete long-term cure is low.

In terms of treatment expectations, doctors usually evaluate the efficacy based on the patient's pathological type, mutation type, disease stage, and previous treatments. The advantage of ametinib is that it targets the T790M resistance mutation and can provide a new treatment option for patients who have relapsed after receiving first- or second-generation EGFR-TKI treatment. While patients are taking amitinib, imaging and biochemical indicators should be reviewed regularly to evaluate drug response and promptly detect signs of resistance or progression, so as to adjust the treatment plan.

In general, ametinib isEGFRMutated lung cancer patients are provided with a highly effective targeted therapy option, but it cannot completely cure lung cancer. The goals of treatment are to slow disease progression, control symptoms, and improve quality of life. Patients and their families should maintain reasonable expectations during the treatment process and cooperate with doctors in individualized medication management and regular monitoring to obtain the best efficacy and improvement in quality of life.

Reference link:https://www.drugs.com